Roivant and Priovant Therapeutics announced that their experimental drug brepocitinib showed promising results in a late-stage clinical trial for the treatment of dermatomyositis.[1] Dermatomyositis is a rare disease that causes painful skin rashes and progressive muscle weakness, making normal daily activities difficult.[1] The drug significantly improved both skin and muscle symptoms and reduced or stopped the need for steroids, which have long-term side effects.[1] In the study, patients taking a daily dose of 30 mg of brepocitinib achieved a mean total improvement score of 46.5 after 52 weeks, compared with 31.2 for placebo.[1] The difference was statistically significant and the benefits were evident after only four weeks.[1] The disease affects fewer than 5,000 people in the US and has limited treatment options, with the only FDA-approved drug being Octagam 10% by Octapharma.[1] The companies plan to file for US approval in the first half of 2026.[1] Brepocitinib is a dual selective inhibitor of TYK2 and JAK1 originally developed by Pfizer.[1][4]